CELLECTRA™ 2000

DEVICE3 trials

Sponsors

Inovio Pharmaceuticals

Conditions

Human Papillomavirus (HPV)Lassa FeverMiddle East Respiratory Syndrome Coronavirus (MERS-CoV)Pre-cancerous Lesions of the VulvaVIN2VIN3Vulvar DysplasiaVulvar High Grade Squamous Intraepithelial Lesion (HSIL)

Phase 1

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

CompletedNCT04093076

Inovio PharmaceuticalsLassa Fever

Start: 2021-01-27End: 2022-10-14Updated: 2022-11-21

Phase 2

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

CompletedNCT03180684

Inovio PharmaceuticalsVulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN) +4

Start: 2017-08-31End: 2020-12-18Updated: 2023-08-25

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

CompletedNCT04588428

Inovio PharmaceuticalsMiddle East Respiratory Syndrome Coronavirus (MERS-CoV)

Start: 2021-06-21End: 2023-01-19Updated: 2026-01-22

Related Papers

Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteers.

2025-11-14

Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.

2025-10-24